(PQB4)SIRT6 Modulates Cancer Metabolism During Aging
(PQB4)SIRT6 Modulates Cancer Metabolism During Aging
批准号:
8850410
负责人:
Raul Mostoslavsky
金额:
$21.1万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-06-01 至 2016-05-31
关键词:
AerobicAgeAgingAging-Related ProcessAnimalsAutomobile DrivingCause of DeathCell RespirationCellsColorectal CancerControl AnimalData SetDeacetylaseDependencyDevelopmentDichloroacetateDiseaseDisease OutcomeElderlyEnergy MetabolismEnzymesExhibitsFamilyFutureGenetic TranscriptionGenetically Engineered MouseGlycolysisGrantGrowthHealthHeart DiseasesHistone DeacetylaseHistonesHumanIncidenceLinkLongevityMalignant NeoplasmsMammalsMetabolicMetabolismMitochondriaMolecularMusMutationNormal tissue morphologyOncogenicPathway interactionsPatientsPhenotypePhysiologicalPopulationProductionProteinsRiskRoleStagingStressTherapeuticTissuesTumor Suppressor ProteinsWarburg Effectaerobic glycolysisaging populationbaseblood glucose regulationcancer cellcancer typecohortcolon cancer patientsdesignglucose metabolismglucose uptakeinhibitor/antagonistmiddle agemortalitymouse modeloverexpressionprotein expressionresponsesugartumortumor growthtumor metabolismtumorigenesis
中文摘要
描述(由申请人提供):衰老与生理功能下降和几种疾病的主要发病率有关。其中,患癌症的风险随着年龄的增长而急剧增加。事实上,它与心脏病一起,是老年人死亡的第一大原因。除了随着年龄的增长而逐渐积累的突变外,人们对衰老过程中癌症发病率增加的分子机制知之甚少。癌细胞的一个显著特征是它们增加的葡萄糖摄取和依赖有氧糖酵解代谢,这是Otto Warburg几十年前描述的一种现象。虽然它是一种潜在的靶向肿瘤的候选药物,但人们对其控制机制知之甚少。有趣的是,这种能量代谢的变化已经在衰老过程中的几个组织中被观察到。然而,连接癌症、衰老和代谢重编程的分子途径仍然缺乏特征。值得注意的是,我们最近发现SIRT6组蛋白去乙酰化酶是糖酵解代谢的中心调节因子:缺乏SIRT6的细胞会经历剧烈的代谢开关,增加乳酸生成,同时减少线粒体呼吸(Mostoslavsky等人,Cell 2006; Zhong等人,Cell 2010)。最近,我们发现SIRT6是一种有效的肿瘤抑制因子,可以抑制癌症代谢(Sebastian et al, Cell 2012)。细胞中SIRT6的失活导致它们在没有激活主要致癌途径的情况下转化,并且在结直肠癌小鼠模型中,缺乏SIRT6会增加肿瘤的数量、大小和侵袭性。重要的是,所有这些表型都可以通过遗传或化学抑制糖酵解而逆转,这突出了糖代谢重编程在肿瘤发生中的驱动作用。在这种情况下,SIRT6在小鼠中的过表达延长了寿命,这种表型可能是由于其肿瘤抑制活性。基于这些发现,我们假设衰老过程中SIRT6表达的降低可以改变组织中的葡萄糖代谢,有利于糖酵解依赖性肿瘤发生和肿瘤生长。在这项资助中,我们将具体:1-研究SIRT6在衰老过程中代谢重编程中的作用。2-通过调节葡萄糖代谢,确定SIRT6作为肿瘤抑制因子在衰老相关癌症中的作用。SIRT6活性的调节可以在未来为我们提供一种潜在的治疗方法来降低年龄人群的癌症发病率。
英文摘要
DESCRIPTION (provided by applicant): Aging is associated with a decline in physiological functions and a major incidence of several diseases. Among them, the risk of suffering from cancer dramatically increases with age. In fact, together with heart diseases, it represents the first cause of death in elder people. Besides the gradual accumulation of mutations with age, very little is known about the molecular mechanisms involved in the increased cancer incidence during aging. A prominent feature of cancer cells is their increased glucose uptake and reliance on aerobic glycolytic metabolism, a phenomenon described by Otto Warburg decades ago. Though it is a potential candidate for targeting against tumors, little is known about the mechanisms controlling it. Interestingly, such change in energy metabolism has been observed in several tissues during aging. However, the molecular pathways linking cancer, aging and metabolic reprogramming remain poorly characterized. Remarkably, we have recently identified the SIRT6 histone deacetylase as a central regulator of glycolytic metabolism: cells lacking SIRT6 undergo a dramatic metabolic switch, increasing lactate production while reducing mitochondrial respiration (Mostoslavsky et al., Cell 2006; Zhong et al., Cell 2010). More recently, we have found that SIRT6 is a potent tumor suppressor that inhibits cancer metabolism (Sebastian et al, Cell 2012). Inactivation of SIRT6 in cells leads to their transformation without the activation of a major oncogenic pathway and, in a mouse model of colorectal cancer, lack of SIRT6 increases the number, size and aggressiveness of tumors. Importantly, all these phenotypes are reversed by genetically or chemically inhibiting glycolysis, highlighting the driving role of glucose metabolism reprogramming in tumorigenesis. In this context, overexpression of SIRT6 in mice extends lifespan, a phenotype that is likely due to its tumor suppressor activity. Based on these findings, we hypothesize that decreased expression of SIRT6 during aging could switch glucose metabolism in tissues, favoring glycolytic-dependent tumorigenesis and tumor growth. In this grant, we will specifically: 1- Study the role of SIRT6 in metabolic reprogramming during aging. 2- Determine the role of SIRT6 as a tumor suppressor in aging-associated cancers by regulating glucose metabolism. Modulation of SIRT6 activity could provide us in the future with a potential therapeutic approach to reduce cancer incidence in the age population.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The histone deacetylase SIRT6 modulates Transcriptional pausing
-
批准号:10317093
-
项目类别:
-
资助金额:$38.81万
-
财政年份:2019
-
负责人:Raul Mostoslavsky
-
依托单位:
The histone deacetylase SIRT6 modulates Transcriptional pausing
-
批准号:10080747
-
项目类别:
-
资助金额:$38.81万
-
财政年份:2019
-
负责人:Raul Mostoslavsky
-
依托单位:
A high throughput assay to identify novel chromatin factors that regulate DNA repair
-
批准号:9767137
-
项目类别:
-
资助金额:$21.06万
-
财政年份:2018
-
负责人:Raul Mostoslavsky
-
依托单位:
Histone tails as an energy reservoir for mitochondrial function
-
批准号:9063076
-
项目类别:
-
资助金额:$20.08万
-
财政年份:2015
-
负责人:Raul Mostoslavsky
-
依托单位:
Histone tails as an energy reservoir for mitochondrial function
-
批准号:8927819
-
项目类别:
-
资助金额:$24.61万
-
财政年份:2015
-
负责人:Raul Mostoslavsky
-
依托单位:
The histone deacetylase SIRT6 functions as a co-repressor of Hif1 alpha in glucos
-
批准号:8664883
-
项目类别:
-
资助金额:$33.29万
-
财政年份:2010
-
负责人:Raul Mostoslavsky
-
依托单位:
Mammalian SIRT6 Is A Master Regulator Of Glucose Homeostasis
-
批准号:8143504
-
项目类别:
-
资助金额:$35.67万
-
财政年份:2010
-
负责人:Raul Mostoslavsky
-
依托单位:
Mammalian SIRT6 Is A Master Regulator Of Glucose Homeostasis
-
批准号:8310218
-
项目类别:
-
资助金额:$35.67万
-
财政年份:2010
-
负责人:Raul Mostoslavsky
-
依托单位:
Mammalian SIRT6 Is A Master Regulator Of Glucose Homeostasis
-
批准号:8534849
-
项目类别:
-
资助金额:$34.42万
-
财政年份:2010
-
负责人:Raul Mostoslavsky
-
依托单位:
Mammalian SIRT6 Is A Master Regulator Of Glucose Homeostasis
-
批准号:8703675
-
项目类别:
-
资助金额:$35.67万
-
财政年份:2010
-
负责人:Raul Mostoslavsky
-
依托单位:
The histone deacetylase SIRT6 functions as a co-repressor of Hif1 alpha in glucos
-
批准号:8462995
-
项目类别:
-
资助金额:$32.13万
-
财政年份:2010
-
负责人:Raul Mostoslavsky
-
依托单位:
The histone deacetylase SIRT6 functions as a co-repressor of Hif1 alpha in glucos
-
批准号:8299619
-
项目类别:
-
资助金额:$33.29万
-
财政年份:2010
-
负责人:Raul Mostoslavsky
-
依托单位:
The histone deacetylase SIRT6 functions as a co-repressor of Hif1 alpha in glucos
-
批准号:8068239
-
项目类别:
-
资助金额:$33.29万
-
财政年份:2010
-
负责人:Raul Mostoslavsky
-
依托单位:
The histone deacetylase SIRT6 functions as a co-repressor of Hif1 alpha in glucos
-
批准号:7865208
-
项目类别:
-
资助金额:$33.63万
-
财政年份:2010
-
负责人:Raul Mostoslavsky
-
依托单位:
Mammalian SIRT6 Is A Master Regulator Of Glucose Homeostasis
-
批准号:7993179
-
项目类别:
-
资助金额:$45.33万
-
财政年份:2010
-
负责人:Raul Mostoslavsky
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
-
批准号:82505677
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.00万元
-
批准年份:2025
-
负责人:吕雨霏
-
依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
-
批准号:82574874
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2025
-
负责人:刘天华
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位: